Skip to main content

Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting

Completed · NCT05956483

Conditions: Bipolar I Disorder

At a glance

Research payments reported, 2025
$11,900
U.S. investigators named
3
Sites paid
3
Planned or actual enrollment
423

About the trial

Sponsor
AbbVie
Dates
Started 2023-12-04; completion 2024-08-16
Results posted
Not yet

Bipolar I Disorder (BP1)is a severe chronic mood disorder characterized by manic and depression. BP1 has high probability of being misunderstood as unipolar major depressive disorder (MDD). The purpose of this study is to confirm Rapid Mood Screener (RMS) effectively classifies participants with BP1. Rapid Mood Screener (RMS) is a brief 6-item clinician-administered checklist, in which a participant's endorsement of four or more questions should trigger further clinical evaluation for BP1. Approximately 404 participants (303 with confirmed unipolar MDD and 101 with confirmed BP1) will be enrolled in the United States. Participants will be answering RMS questionnaire and accuracy will be m…

From ClinicalTrials.gov, last updated 2024-08-20. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $11,900 in research payments for this study in 2025 (6 payments).

Products named: Vraylar

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • J&a Clinical Research LLC $7,650
  • Uhc Research LLC $3,400
  • Elligo Health Research Inc $850

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.